- Carlyle Group is in advanced talks to buy Granules India, a pharmaceuticals maker, for ~$1B, India's CNBC-TV18 reports, citing three sources with direct knowledge of the deal.
- That would add on to Carlyle's pharmaceutical industry investments after recently acquiring Sequent Scientific and a minority stake in Piramal Pharma.
It's not clear how Granules might grow Carlyle's COVID-19 profit plans. Granules does have a clinical research and manufacturing arm as well as a number of FDA approved drug production sites.
Where Americans see high costs, Carlyle sees grand profits.